Cellular senescence predicts treatment outcome in metastasised colorectal cancer
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cellular senescence is a terminal cell-cycle arrest that occurs in response to activated oncogenes and DNA-damaging chemotherapy. Whether cancer cell senescence at diagnosis might be predictive for treatment outcome is unknown. METHODS: A senescence index (SI) was developed and used to retrospectively correlate the treatment outcome of 30 UICC stage IV colorectal cancer (CRC) patients with their SI at diagnosis. RESULTS: 5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with SI-positive tumours before therapy (median 12.0 vs 6.0 months; P=0.044). CONCLUSION: Cancer cell senescence predicts treatment outcome in metastasised CRC. Prospective analyses of larger patient cohorts are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and are a characteristic of therapy-induced senescence (Haugstetter et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Haugstetter et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most studies, senescence is assessed in ex vivo cultures or fresh samples by SAb -gal staining or indirect markers in formalin-fixed tissues”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Haugstetter et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colon adenomas, which are stable precursor lesions of invasive colon cancer, were found to be negative for the proliferation marker Ki67 and positive for SA- β- gal 87,88 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Supporting this notion, the burden of senescent cells in tissues increases significantly with age in mice, primates, and humans,27 and they can be found in both benign and malignant tumours.31–35”
From Paracrine roles of cellular senescence in promoting tumourigenesis (2018) · cites this paper as [32]
In the citing paper
“Since senescent cells are generally abundant in benign tumours and also present at low numbers in several malignancies,31–34,57 their paracrine activities could contribute to tumour progression and cancer metastasis.”
From Paracrine roles of cellular senescence in promoting tumourigenesis (2018) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 3×
“…(2010) 103(4), 505 – 509 & 2010 Cancer Research UK M o le c u la r D ia g n o stic s Senescence-associated b-galactosidase activity Senescence-associated b-galactosidase activity was detected at pH 6.0 in cryo-preserved cells or tissue sections as described (Dimri et al, 1995; Braig et al, 2005).”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 6×
“…in a well-established OIS reference model system – sections of either snap-frozen or FFPE pellets of Ras-senescent vs proliferating fibroblasts – that allowed us to compare SA-b-gal staining and potential immunohistochemical surrogate markers in the same material side by side (Serrano et al, 1997).”
BackgroundMethodInfluentialDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 3×
“Oncogene-induced senescence is mediated through an oncogene-evoked DNA damage response (DDR) (Bartkova et al, 2005, 2006; Gorgoulis et al, 2005), thereby explaining why DNA-damaging chemotherapy produces senescence as well (Chang et al, 1999; Schmitt et al, 2002).”
BackgroundRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“…adenoma samples, we generated a senescence surrogate score (SI) based on the expression of p-ERK, HP1g and PAI-1 – all of them previously linked to OIS (Serrano et al, 1997; Lin et al, 1998; Narita et al, 2003) – that recapitulated SA-b-gal reactivity and adenoma senescence (Figure 1C; Figure 2).”
MethodBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 2×
“A third cancer-related growth condition is oncogene-induced senescence (OIS), a terminal cell-cycle arrest initiated by activated Ras-type oncogenes that acts as a tumour-suppressive barrier in pre-malignant lesions in vivo (Braig et al., 2005; Collado & Serrano, 2010; Michaloglou et al., 2005; Reimann et al., 2010).”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · cited 3×
“Oncogene-induced senescence is mediated through an oncogene-evoked DNA damage response (DDR) (Bartkova et al, 2005, 2006; Gorgoulis et al, 2005), thereby explaining why DNA-damaging chemotherapy produces senescence as well (Chang et al, 1999; Schmitt et al, 2002).”
BackgroundOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 7×
“Oncogene-induced senescence is mediated through an oncogene-evoked DNA damage response (DDR) (Bartkova et al, 2005, 2006; Gorgoulis et al, 2005), thereby explaining why DNA-damaging chemotherapy produces senescence as well (Chang et al, 1999; Schmitt et al, 2002).”
BackgroundMethodInfluentialOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220 · cited 4×
“…(2010) 103(4), 505 – 509 & 2010 Cancer Research UK M o le c u la r D ia g n o stic s Senescence-associated b-galactosidase activity Senescence-associated b-galactosidase activity was detected at pH 6.0 in cryo-preserved cells or tissue sections as described (Dimri et al, 1995; Braig et al, 2005).”
BackgroundMethodInfluentialSelf-citationKi67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207 · cited 2×
“Although relevant as a prognosticator, the value of utilizing the mitotic index to predict treatment outcome is very limited (see (Brown & Attardi, 2005; Schmitt, 2003; Schmitt, 2007; Yerushalmi et al., 2010) for review and references therein).”
BackgroundRoth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158 · cited 2×
“…(P¼ 0.035) in the senescent group (Figure 1D, inset), suggesting that Ras mutations, if associated with a senescent phenotype, may not necessarily serve as a predictor of poor outcome, as reported by several studies in the past (Benhattar et al, 1993; Andreyev et al, 1998, 2001; Roth et al, 2010).”
ResultInfluential
Cited by
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
“High phospho-ERK levels were detected in pre-neoplastic lesions, rich in senescent cells such as mel-anocytic nevi and benign prostatic hyperplasia (BPH) (De-scheˆnes-Simard et al., 2013), and are a characteristic of therapy-induced senescence (Haugstetter et al., 2010).”
Self-citationThe essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
“In line with the idea that OIS represents a barrier for cancer development, a senescence index of tumor cells has been associated with better treatment outcome in high-grade colorectal cancer (Haugstetter et al. 2010).”
BackgroundSenescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Self-citationSenescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Self-citationThe dynamic nature of senescence in cancer
Lee, S., & Schmitt, C. A. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0249-2 · Cited by 588
Self-citationGeorgakopoulou, E., Tsimaratou, K., Evangelou, K., Fernandez, M.-P., Zoumpourlis, V, Trougakos, I., Kletsas, D., Bartek, J., Serrano, M., & Gorgoulis, V. (2012) · Aging · doi:10.18632/aging.100527 · Cited by 390
“Furthermore, there is evidence that presence of senescent cells in certain malignant tumors may be a sign of better prognosis [42].”
BackgroundGlobal reorganization of the nuclear landscape in senescent cells
Chandra, T., Ewels, P. A., Schoenfelder, S., Furlan-Magaril, M., Wingett, S. W., Kirschner, K., Thuret, J.-Y., Andrews, S., Fraser, P., & Reik, W. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.055 · Cited by 348
“Markers of senescence, such as p16 upregulation, are particularly prevalent in benign lesions and are often lost upon malignancy (Braig et al., 2005; Haugstetter et al., 2010; Michaloglou et al., 2005).”
BackgroundSenescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Senescence: a new weapon for cancer therapy
Acosta, J. C., & Gil, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.006 · Cited by 223
Cellular senescence: the sought or the unwanted?
Sun, Y., Coppé, J.-P., & Lam, E. W.-F. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.002 · Cited by 208
The Cancer SENESCopedia: A delineation of cancer cell senescence
Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L., Schepers, A., Wang, C., Jin, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109441 · Cited by 201
“This is an open access article under the CC BY-N halt tumor growth, and the SASP can create an immunogenic environment (Greten and Eggert, 2017; Haugstetter et al., 2010; Schmitt et al., 2002).”
BackgroundParacrine roles of cellular senescence in promoting tumourigenesis
Gonzalez-Meljem, J. M., Apps, J. R., Fraser, H. C., & Martinez-Barbera, J. P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0066-1 · Cited by 183
Tumor cell escape from therapy-induced senescence
Saleh, T., Tyutyunyk-Massey, L., Murray, G. F., Alotaibi, M. R., Kawale, A. S., Elsayed, Z., Henderson, S. C., Yakovlev, V., Elmore, L. W., Toor, A., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.013 · Cited by 182
Senescence-Associated β-Galactosidase Detection in Pathology
Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022) · Diagnostics · doi:10.3390/diagnostics12102309 · Cited by 182
“Reproduced from [27] under the terms of the Creative Commons CC BY license; (b)”
BackgroundMethodInfluentialPatterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy
Hsu, C.-H., Altschuler, S. J., & Wu, L. F. (2019) · Cell · doi:10.1016/j.cell.2019.05.041 · Cited by 181
“Clinically, there is growing evidence that therapy-induced senescence occurs in tumors and is associated with improved clinical outcomes (Collado and Serrano, 2010; Haugstetter et al., 2010; Roninson, 2003; Schmitt et al., 2002).”
BackgroundAneuploidy as a promoter and suppressor of malignant growth
Vasudevan, A., Schukken, K. M., Sausville, E. L., Girish, V., Adebambo, O. A., & Sheltzer, J. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00321-1 · Cited by 177
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies
Lucas, V., Cavadas, C., & Aveleira, C. A. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000622 · Cited by 160
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 175
Polyploidy road to therapy‐induced cellular senescence and escape
Wang, Q., Wu, P. C., Dong, D. Z., Ivanova, I., Chu, E., Zeliadt, S., Vesselle, H., & Wu, D. Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.27810 · Cited by 129
“Of note, a recent clinicopathological study of colorectal cancer patients suggests that evidence of senescence in tumors prior to treatment may be predictive of improved progression-free survival.(49) As oncogene-mediated senescence in precancerous states has been shown to suppress transformation, this finding confirm…”
ResultSenolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 136
“(cid:129) SASP factors (Copp´e et al., 2008) by RQ-PCR, multiplex protein detection, or, e.g., IL-8 or PAI-1 by immunostaining (Haugstetter et al., 2010; Lee et al., 2021).”
BackgroundInfluentialSelf-citationSenescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
Velarde, M. C., Demaria, M., & Campisi, J. (2013) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000343572 · Cited by 112
“Indeed, the induction of senescence in response to chemotherapy predicted a better outcome in human patients with advanced colon cancer [52].”
BackgroundReshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies
D’Ambrosio, M., & Gil, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.05.010 · Cited by 119
Biological functions of therapy-induced senescence in cancer
Fitsiou, E., Soto-Gamez, A., & Demaria, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.021 · Cited by 111
“In colon adenomas and carcinomas, spontaneous senescence induction resulted in longer progression-free survival period after treatment with 5-fluorouracil/leucovorin in comparison to non-senescent tumors [51].”
BackgroundTato-Costa, J., Casimiro, S., Pacheco, T. R., Pires, R., Fernandes, A., Alho, I., Pereira, P., Costa, P., Castelo, H. B., Ferreira, J. A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.09.003 · Cited by 126
“Despite the powerful paracrine effects exerted by SASs in vitro,(15-19) to what extent senescent cancer cells present within tumors influence the microenvironment and, eventually, cancer progression has remained elusive.(12,20,21) We initially interrogated the cytokine composition of the SAS from colon cancer cells (H…”
BackgroundMorphological and Functional Characteristic of Senescent Cancer Cells
Sikora, E., Mosieniak, G., & Alicja Sliwinska, M. (2016) · Current Drug Targets · doi:10.2174/1389450116666151019094724 · Cited by 99
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations
Jing, H., Kase, J., Dörr, J. R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., et al. (2011) · Genes & Development · doi:10.1101/gad.17620611 · Cited by 99
“Cellular senescence not only acts as a tumor-suppressive principle, but contributes to the outcome of cancer therapy in vivo (Schmitt et al. 2002; Haugstetter et al. 2010).”
BackgroundSelf-citationCellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
“This was illustrated in an in vivo p53 wild-type breast cancer model where TIS was induced instead of cell death after chemotherapy treatment and resulted in minimal regression of the tumor and early relapse through the secretion of protumorigenic SASP [266].”
BackgroundInfluentialThe Senescence–Stemness Alliance – A Cancer-Hijacked Regeneration Principle
Milanovic, M., Yu, Y., & Schmitt, C. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.09.001 · Cited by 92
Self-citationSenescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
Choi, Y. W., Kim, Y. H., Oh, S. Y., Suh, K. W., Kim, Y., Lee, G., Yoon, J. E., Park, S. S., Lee, Y., Park, Y. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202002497 · Cited by 105
Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
“It has, however, been reported that tumor predisposed to senescence may be discovered prior to treatment and that this might in fact affect treatment outcome (160).”
BackgroundWagner, J., Damaschke, N., Yang, B., Truong, M., Guenther, C., McCormick, J., Huang, W., & Jarrard, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124366 · Cited by 83
“In colon cancer, tumor biopsies show senescent areas after 5-Fluorouracil and Leucovorin treatment demonstrate longer progression-free survival than patients without senescence [28].”
BackgroundTargeting tumor cell senescence and polyploidy as potential therapeutic strategies
Saleh, T., Carpenter, V. J., Bloukh, S., & Gewirtz, D. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.010 · Cited by 74
Lee, S. Y., Ju, M. K., Jeon, H. M., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1027453 · Cited by 71
Ewald, J. A., Desotelle, J. A., Church, D. R., Yang, B., Huang, W., Laurila, T. A., & Jarrard, D. F. (2013) · The Prostate · doi:10.1002/pros.22571 · Cited by 63
“Without single markers that uniquely identify senescence, we adopted a strategy of assessing multiple surrogate markers associated with the senescence phenotype [22].”
BackgroundMethodCellular Senescence in Liver Disease and Regeneration
Ferreira-Gonzalez, S., Rodrigo-Torres, D., Gadd, V. L., & Forbes, S. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0040-1722262 · Cited by 59
Enhanced killing of therapy‐induced senescent tumor cells by oncolytic measles vaccine viruses
Weiland, T., Lampe, J., Essmann, F., Venturelli, S., Berger, A., Bossow, S., Berchtold, S., Schulze‐Osthoff, K., Lauer, U. M., & Bitzer, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28350 · Cited by 55
“A recent study suggested that the presence of senescent tumor cells even might be a predictive marker indicating a favorable outcome of chemotherapeutic treatments.(31) However, despite the inability to proliferate, concerns exist that senescent cells might contribute to therapy resistance or even tumor progression by…”
BackgroundCancer cell senescence: a new frontier in drug development
Cairney, C. J., Bilsland, A. E., Evans, T. R. J., Roffey, J., Bennett, D. C., Narita, M., Torrance, C. J., & Keith, W. N. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.019 · Cited by 50
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
Taschner‐Mandl, S., Schwarz, M., Blaha, J., Kauer, M. O., Kromp, F., Frank, N., Rifatbegovic, F., Weiss, T., Ladenstein, R. L., HOHENEGGER, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6527 · Cited by 49
Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars
Martínez‐Zamudio, R. I., Stefa, A., de Freitas, J. A. N. L. F., Vasilopoulos, T., Simpson, M., Doré, G. R. G., Roux, P., Galan, M. A., Chokshi, R. J., Bischof, O., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100293 · Cited by 52
Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis
Garbarino, O., Lambroia, L., Basso, G., Marrella, V., Franceschini, B., Soldani, C., Pasqualini, F., Giuliano, D., Costa, G., Peano, C., et al. (2023) · Aging Cell · doi:10.1111/acel.13853 · Cited by 43
“Additionally, studies on chemotherapynaive metastatic patients are rare, except Haugstetter et al. (2010), who described senescence as a common feature in CRLM and having a positive prognostic role in patient survival.”
BackgroundKim, Y. H., & Park, T. J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.295 · Cited by 44
“However, in vivo, senescent cells appear normal and lack such morphological changes (25-28).”
BackgroundMethodInfluentialSaleh, T., Alhesa, A., Al-Balas, M., Abuelaish, O. M., Mansour, A. T., Awad, H., El‐Sadoni, M., Carpenter, V. J., & Azab, B. (2021) · Bioscience Reports · doi:10.1042/bsr20210079 · Cited by 40
“Moreover, a previous study has shown that the TIS marked by IHC staining for Ki-67, plasminogen activator inhibitor-1, and SA-β -gal was detected in 30 samples of colorectal cancer [70].”
Insights into the role of senescence in tumor dormancy: mechanisms and applications
DeLuca, V. J., & Saleh, T. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10082-6 · Cited by 41
“1 3 demonstrated as having up to 40% senescent cells; this includes studies on patient samples derived from breast cancer patients treated with doxorubicin and cyclophosphamide [41], prostate cancer patients treated with mitoxantrone [42] or androgen deprivation [43], colorectal cancer patients after receiving 5-fluor…”
BackgroundBlute, M. L., Damaschke, N., Wagner, J. L., Yang, B., Gleave, M. E., Fazli, L., Shi, F., Abel, E. J., Downs, T. M., Huang, W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172048 · Cited by 36
Senescence in cancer: Advances in detection and treatment modalities
Billimoria, R., & Bhatt, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115739 · Cited by 38
Biggers, J., Nguyen, T. T. L., Di, X. M., Gupton, J. T., Henderson, S. C., Emery, S. M., Alotaibi, M. R., White, K. L., Brown, R., Almenara, J. A., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2024-6 · Cited by 33
Therapy-induced senescent tumor cells in cancer relapse
Song, K., Wang, J., & Huang, D. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.09.001 · Cited by 57
Apoptosis or senescence? Which exit route do epithelial cells and fibroblasts preferentially follow?
Georgakopoulou, E. A., Evangelou, K., Havaki, S., Townsend, P. A., Kanavaros, P., & Gorgoulis, V. G. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.03.010 · Cited by 35
“Notably, the presence of senescent cells in metastasized colorectal carcinoma was considered predictive of a better prognosis, suggesting putative therapeutic exploitation (Haugstetter et al., 2010).”
BackgroundEl‐Sadoni, M., Shboul, S. A., Alhesa, A., Shahin, N. A., Alsharaiah, E., Ismail, M. A., Ababneh, N. A., Alotaibi, M. R., Azab, B., & Saleh, T. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04523-w · Cited by 28
“Based on the use of three oncogene-induced, rather than therapyinduced, senescence surrogate proteins, namely, p-ERK, HP1γ and PAI-1 [91, 92], evidence of TIS was recorded in 12 of 30 samples (40%) [90].”
BackgroundNagineni, C. N., Naz, S., Choudhuri, R., Chandramouli, G. V. R., Krishna, M. C., Brender, J., Cook, J. A., & Mitchell, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094835 · Cited by 29
“Colorectal cancer patients achieved significantly longer progressive-free survival when presenting with more senescence positive cells in tumors before therapy [1,24].”
BackgroundKim, B. C., YOO, H. J., Lee, H., Kang, K. A., Jung, S. H., Lee, H. J., Lee, M., Park, S. W., JI, Y.-H., Lee, Y.-S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3069 · Cited by 29
Seignez, C., Martin, A., Rollet, C.-E., Racoeur, C., Scagliarini, A., Jeannin, J., Bettaïeb, A., & Paul, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2556 · Cited by 28
“com/oncotarget CRC patients achieved a significantly longer progression free survival when presenting with senescence indexpositive tumors before treatment [23].”
BackgroundThe Myc/macrophage tango: Oncogene-induced senescence, Myc style
Lee, S., Schmitt, C. A., & Reimann, M. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.002 · Cited by 32
Self-citationResveratrol induces DNA damage-mediated cancer cell senescence through the DLC1–DYRK1A–EGFR axis
Ma, F., Ma, Y., Liu, K., Gao, J., Li, S., Sun, X., & Li, G. (2022) · Food & Function · doi:10.1039/d2fo01188c · Cited by 24
Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663898 · Cited by 27
“These findings are extremely relevant given that tumor cell senescence is increasingly being observed in patients who were treated successfully for a variety of cancers (20, 40, 41).”
BackgroundPan, B., Zhao, D., Liu, Y., Li, N., Song, C., Li, N., Li, X., Li, M., & Zhao, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01459-6 · Cited by 23
Impact of Cellular Senescence in Aging and Cancer
Provinciali, M., Cardelli, M., Marchegiani, F., & Pierpaoli, E. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213805219739 · Cited by 26
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer
Mourkioti, I., Polyzou, A., Veroutis, D., Theocharous, G., Lаgopati, N., Gentile, E., Stravokefalou, V., Thanos, D.-F., Havaki, S., Kletsas, D., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02769-z · Cited by 23
“Radiation therapy and a variety of anti-cancer agents have been shown to trigger various cellular responses, including the induction of senescence in cancer cells [11].”
BackgroundAlhaddad, L., Osipov, A. N., & Leonov, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113577 · Cited by 22
“Senescent cells have been reported to contribute to the composition of pre-malignant [466–468] and malignant lesions [469]; thus, they play an indubitable role in tumor cell fate [470,471].”
BackgroundClostridioides difficile Toxin B Induced Senescence: A New Pathologic Player for Colorectal Cancer?
Fettucciari, K., Fruganti, A., Stracci, F., Spaterna, A., Marconi, P., & Bassotti, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098155 · Cited by 21
Kellers, F., Fernandez, A., Konukiewitz, B., Schindeldecker, M., Tagscherer, K. E., Heintz, A., Jesinghaus, M., Roth, W., & Foersch, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.865230 · Cited by 23
“There is evidence to suggest that senescence detection might be of predictive value for CRC patients (50), however an extensive clinical study to evaluate the prognostic potential of senescence markers had been missing.”
BackgroundResultEwald, J. A., & Jarrard, D. F. (2012) · Translational Oncology · doi:10.1593/tlo.12181 · Cited by 22
“Recently, senescence in colorectal cancer patients correlated with longer tumor-free survival after 5-fluorouracil/leucovorin treatment [23].”
BackgroundTargeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer
Rowell, M., Deschênes‐Simard, X., Lopes‐Paciencia, S., Calvé, B. L., Kalegari, P., Mignacca, L., Ruiz, A. F., Guillon, J., Lessard, F., Bourdeau, V., et al. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2278945 · Cited by 19
“Schmitt and colleagues reported that pERK levels correlated with the induction of senescence in colorectal cancer patients treated with 5FU, one of the components of FOLFIRINOX [56].”
BackgroundPrognostic significance of a signature based on senescence-related genes in colorectal cancer
Ungvari, Z. I., Ungvari, A., Bianchini, G., & Győrffy, B. (2024) · GeroScience · doi:10.1007/s11357-024-01164-6 · Cited by 16
“Further, in stage IV colorectal cancer patients, an increased tumor senescence burden was shown to be associated with a significantly longer progression-free survival in response to treat-ment with 5-Fluorouracil/leucovorin therapy [30].”
BackgroundMacroH2A suppresses the proliferation of the B16 melanoma cell line
Lei, S., Long, J., & LI, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2482 · Cited by 18
Cellular Senescence in Liver Cancer: How Dying Cells Become “Zombie” Enemies
Gazzillo, A., Volponi, C., Soldani, C., Polidoro, M. A., Franceschini, B., Lleò, A., Bonavita, E., & Donadon, M. (2023) · Biomedicines · doi:10.3390/biomedicines12010026 · Cited by 15
Senescence-related genes as prognostic indicators in breast cancer survival
Ungvari, Z. I., Ungvari, A., Fekete, M., Kiss, C., & Győrffy, B. (2024) · GeroScience · doi:10.1007/s11357-024-01384-w · Cited by 16
“Among these mechanisms, cellular senescence has garnered significant attention for its paradoxical role in both tumor suppression and promotion [5–8].”
Santoni, G., Amantini, C., Nabissi, M., Maggi, F., Arcella, A., Marinelli, O., Eleuteri, A. M., Santoni, M., & Morelli, M. B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.578928 · Cited by 13
Li, H., Ni, H., Li, Y., Zhou, A., Qin, X., Li, Y., Che, L., Mo, H., Qin, C., & Li, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01984-7 · Cited by 15
“Co-treatment of IFN-γ and TNF-α induces PANoptosis of SA-b-gal-positive (blue) cell Co-treatment of IFN-γ and TNF-α can induce senescence in cells, we analysed whether senescent cells was sensitive to co-treatment of IFN-γ and TNF-α to induce cell death(18-20).”
Cellular senescence: Silent operator and therapeutic target in cancer
Ramu, D., Teoh, W. S., Hirpara, J. L., & Pervaiz, S. (2021) · IUBMB Life · doi:10.1002/iub.2460 · Cited by 13
“However, with the advancements in identifying novel biomarkers and the speed with which fresh primary tissues can be processed, the presence of a significant population of senescent cells within bulk tumors has been reported.(20) Notably, these senescent populations were mainly associated with tumors that did not have…”
BackgroundNon‐pituitary growth hormone enables colon cell senescence evasion
Chesnokova, V., Zonis, S., Apaydın, T., Barrett, R. J., & Melmed, S. K. (2024) · Aging Cell · doi:10.1111/acel.14193 · Cited by 10
“Senescence evasion in precancerous cells may also lead to benign- to-neoplastic progression (Haugstetter et al., 2010; Lee & Schmitt, 2019 ; Michaloglou et al., 2005 ; Yu et al., 2018).”
Bridger, J. M., & Foster, H. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-62532-0_5 · Cited by 11
“Chromatin may be organised within senescence associated heterochromatin foci (SAHF) (Morris et al. 2019; Lenain et al. 2017; Braig et al. 2005; Michaloglou et al. 2005; Haugstetter et al. 2010).”
BackgroundPD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis
Zhang, L.-Z., Yang, J., Xia, H., Huang, J., Liu, H.-M., Wu, M., Liu, B., Wang, W.-M., & Chen, G. (2023) · Journal of Dental Research · doi:10.1177/00220345231165209 · Cited by 10
“However, recent studies have demonstrated that an aberrant accumulation of senescent cells negatively affects regenerative capacities and creates a proinflammatory milieu favorable for the onset and progression of various cancers (Milde-Langosch et al. 2001; Roberson et al. 2005; Davalos et al. 2010; Haugstetter et al…”
BackgroundWalen, K. H. (2013) · Springer eBooks · doi:10.1007/978-94-007-5958-9_18 · Cited by 9
Mcl-1 and tumor cell persistence
Pfannenstiel, L. W., & Gastman, B. (2014) · Oncotarget · doi:10.18632/oncotarget.3035 · Cited by 10
Yang, P., Yin, K., Zhong, D., Liao, Q., & Li, K. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2903 · Cited by 9
Rademacher, D. J., Exline, J. E., & Foecking, E. M. (2025) · Biomedicines · doi:10.3390/biomedicines13061400 · Cited by 10
Kim, Y., Lee, J.-H., Lee, C., & Lawler, S. E. (2022) · Journal of Mathematical Biology · doi:10.1007/s00285-022-01850-z · Cited by 7
“However, senescent tumor cells (STCs) have been identified in both benign and malignant tumors (Haugstetter et al. 2010) and STCs in malignant tumors were shown to play a pivotal role in cancer progression (Kim et al. 2017a).”
BackgroundTranscription factor network dynamics during the commitment to oncogene-induced senescence
Vasilopoulos, T., & Martínez‐Zamudio, R. I. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2024.1423454 · Cited by 5
“Given their considerable impact on the outcome of carcinogenesis (Haugstetter et al., 2010; Eggert et al., 2016; Yu et al., 2018; Martinez-Zamudio et al., 2020; Martinez-Zamudio et al., 2023), understanding the mechanisms that commit cells to the OIS state early upon oncogene hyperactivation can…”
Odeh, A., Eddini, H., Shawasha, L., Chaban, A., Avivi, A., Shams, I., & Manov, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065132 · Cited by 7
“Paracrine signaling of senescent stromal cells, which are abundant in benign tumors and are present in cancer [32,33], affects the malignant properties of tumor cells, mainly enhancing their proliferation and invasiveness [34–36].”
BackgroundNovel radiation and targeted therapy combinations for improving rectal cancer outcomes
Pennel, K. A. F., Dutton, L. R., Melissourgou-Syka, L., Roxburgh, C. S. D., Birch, J. L., & Edwards, J. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.15 · Cited by 7
“120).”
CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
Ye, X., Liu, X., Gao, M., Gong, L., Tian, F., Shen, Y., Hu, H., Sun, G., Zou, Y., & Gong, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638802 · Cited by 7
Farrokhnazar, E., Moghbelinejad, S., Najafipour, R., & Teimoori‐Toolabi, L. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41933 · Cited by 5
Senescence Associated Heterochromatic Foci: SAHF
Chandra, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-38882-3_9 · Cited by 8
Zhang, J., Shen, Z., Song, Z., Luan, J., Li, Y., & Zhao, T. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.554833 · Cited by 4
“An accumulation of genetic and epigenetic alterations can also facilitate the development of colon cancer from normal mucosa (Hong, 2018).”
BackgroundRobust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells
Miciak, J. J., Petrova, L., Sajwan, R., Pandya, A., Deckard, M., Munoz, A. J., & Bunz, F. (2025) · Oncotarget · doi:10.18632/oncotarget.28690 · Cited by 5
“This conclusion is supported by observations of high levels of senescence in CRC precursor lesions that typically retain TP53 [63, 64].”
Cellular Senescence in Cancer: Mechanisms, Roles in Tumor Progression, and Therapeutic Implications
Yan, J., Zhang, Y., Mao, G., Yu, J., Zhou, T., & Hao, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70029 · Cited by 3
Zelluläre Seneszenz im kolorektalen Karzinom
Foersch, S. (2017) · Der Pathologe · doi:10.1007/s00292-017-0357-y · Cited by 3
Picallos-Rabina, P., Silva‐Álvarez, S. D., Antelo-Iglesias, L., Triana-Martínez, F., & Collado, M. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_5 · Cited by 3
Silva‐Álvarez, S. D., & Collado, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30066-9 · Cited by 5
Silva‐Álvarez, S. D., & Collado, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00219-4 · Cited by 3
Zhang, N., Zhao, R., Zhong, X., Dong, Q., Liu, Y., Yu, K., Han, L., Meng, F., Wu, J., Chen, Q., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68143-z · Cited by 7
Prognostic impact of the combination of p16INK4a, p21 and Immunoscore in rectal cancer
Nakao, T., Shimada, M., Yoshikawa, K., Tokunaga, T., Nishi, M., Kashihara, H., Takasu, C., Wada, Y., & Yoshimoto, T. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02519-x · Cited by 2
“While previous studies reported that the measurement of cellular senescence might be a predictive factor in colorectal cancer patients [12], the clinical significance of the contribution of cellular senescence to colorectal carcinogenesis has not yet been studied in large patient cohorts.”
Current Methodologies to Assess Cellular Senescence in Cancer
Laouris, P., & Muñoz‐Espín, D. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4426-3_2 · Cited by 4
Balancing senescence and apoptosis: therapeutic insights into aging and cancer
Jan, N., Sofi, S., Mir, A. A., Masoodi, G., & Mir, M. A. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05355-3 · Cited by 4
“Ki67, a proliferation marker, was found to be negative in colon adenomas, stable precursor lesions of invasive colon cancer, but positive for SA-β-gal [106].”
Metadata
- Authors
- Haugstetter, A. M., Loddenkemper, C., Lenze, D., Gröne, J., Standfuß, C., Petersen, I., Dörken, B., & Schmitt, C. A.
- Affiliations
- Stiftung Charité (DE)
- Technical University of Munich (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Friedrich Schiller University Jena (DE)
- Max Delbrück Center (DE)
- Corresponding author
- Schmitt, C A
- Venue
- British Journal of Cancer
- Published
- 2010-07-13
- Volume
- 103
- Issue
- 4
- Pages
- 505-509
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2939783
- OpenAlex
- W2049256375
- Cited by
- 117
- References
- 28
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 11 · 2023: 16 · 2022: 8 · 2021: 11 · 2020: 9 · 2019: 4 · 2018: 8 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 4 · 2012: 7
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- Deutsche Krebshilfe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- cellular senescence, colorectal cancer, metastatic colorectal cancer, treatment outcome prediction, 5-fluorouracil, leucovorin, progression-free survival, cell cycle arrest
- MeSH terms
- Leucovorin, Fluorouracil, Humans, Predictive Value of Tests, Prognosis, Colorectal Neoplasms, Treatment Outcome, Cellular Senescence, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.